Company & Sponsor Intelligence
Luye Pharma Group Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting0
Completed1
Countries1
Therapeutic footprint
parkinsons
Indexed studies
NCT04571164A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
parkinsons · ChinaPHASE3
parkinsons · ChinaPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →